Rectifying function, restoring hope

Jason Rhodes is a Partner at Atlas Venture and focuses on creating and building novel therapeutics companies. Jason is the Executive Chair of the Board of Rectify. Jason was the founding CEO of Generation Bio and Dyne Therapeutics. He is also on the boards of Replimune, Accent Therapeutics, and Be Biopharma. He was the chair and founding CEO of Disarm Therapeutics, acquired by Eli Lilly. Previously, Jason held leadership positions at Epizyme, where he was President and built the company from early-stage research into the clinic and through a successful IPO, and at Alnylam Pharmaceuticals, where he led business development. Jason was also a founder and partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including FoldRx, acquired by Pfizer. He is a member of the advisory board of the Harvard Institute for RNA Medicine, the Blavatnik Fund at Yale University, and the Berklee College of Music Presidential Advisory Council. Jason received his B.A. from Yale University and his M.B.A. from the Wharton School of the University of Pennsylvania.

Rajesh (Raj) Devraj, Ph.D., is President and Chief Executive Officer of Rectify and a Venture Partner at Atlas Venture. Throughout his career, he has been focused on creating and building groundbreaking biotech companies. Prior to Rectify, Raj co-founded Disarm Therapeutics with Atlas and served as its Chief Scientific Officer prior to its acquisition. Before Disarm, he served as Chief Scientific Officer of Atlas-founded Padlock Therapeutics. Prior to his tenure at Atlas, Raj served in senior executive roles at Euclises & Deciphera Pharmaceuticals and at Jubilant Life Sciences. In addition, Raj spent 14 years in positions of increasing responsibility with Pfizer Global R&D and the legacy Pharmacia and Searle companies. Raj also serves on the boards of directors for several biotech companies. Over a 25-year career in large pharma and biotech, Raj has led discovery, early clinical development and strategic planning teams that have advanced multiple candidates into clinical trials for refractory cancers, autoimmune diseases, IPF, diabetic nephropathy, COPD, and pain. Raj received his B.S. in Pharmacy from University of Mumbai, and Ph.D. in Medicinal Chemistry from Duquesne University.

Marco Boorsma, Ph.D., is a General Partner at Forbion. He has a background in molecular biology and biotechnology and brings operational and business development experience from both small and large businesses. Before joining Forbion, he was Business Development Director and Project Manager at DSM Pharmaceutical Products and a Scientist at Cytos Biotechnology in Switzerland. Marco also serves on the board of directors of Escalier Biosciences, NorthSea Therapeutics, Milestone Pharmaceuticals, RSPR Pharma, Prexton Therapeutics, and Engene, and is an observer to the board of directors of Exosome Diagnostics and Oxyrane. Previously, he served on the board of directors of Dezima Pharma, which was sold to Amgen, and on the board of directors of Akarna Therapeutics, which was sold to Allergan. After obtaining a master’s degree in Molecular Biology from the University of Groningen, he received his Ph.D. in Biotechnology from the ETH Institute for Technology in Zürich, and completed part of his research at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge, UK.

Otello Stampacchia, Ph.D., founded Omega Funds and leads the firm’s investor relations and strategic initiatives. He is a member of the firm’s investment committee and is also heavily involved in a number of Omega’s therapeutic areas of interest, particularly in oncology, rare diseases and inflammatory disorders. Previously, Otello was in charge of life sciences direct investments and diligence for healthcare venture fund of fund investments at AlpInvest Partners, one of the largest private equity asset managers worldwide. Before AlpInvest, he was the Portfolio Manager of the Lombard Odier Immunology Fund, a $3 billion listed investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previously, Otello was a member of the HealthCare corporate finance and M&A team at Goldman Sachs (London and New York offices). Before Goldman, he helped co-found the healthcare investment activities at Index Securities (now Index Ventures). Otello has a Ph.D. in Molecular Biology from the University of Geneva, holds a European Doctorate in Biotechnology from the EU, and obtained an MSc in Genetics from the University of Pavia.

Vikas is a Venture Partner at Longwood Fund where he focuses on growth stage investments in late preclinical and clinical stage biotechnology companies. He has been working in the biotech industry for 20 years, with a particular focus on corporate strategy, capital formation, corporate partnerships, and M&A for early-stage therapeutics companies. Prior to joining Longwood Fund, Vikas was a Managing Partner at Trekk Venture Partners, where he led investments in biotechnology companies developing life-changing medicines. Previously, Vikas was Senior Vice President of Business Development for Pandion Therapeutics. He initially joined Pandion as a Board member and investor in 2018, and ultimately joined the company full-time in 2019 taking the company through a research collaboration with Astellas, an IPO, and the company’s acquisition by Merck for $1.85 billion in 2021. Vikas joined Pandion from SR One, where he invested in and served on the boards of 19 early-stage biotech companies. Earlier in his career, Vikas was a Consultant at McKinsey & Co’s Pharmaceutical practice, a co-founder of Extera Partners, and a Business Development Manager at Infinity Pharmaceuticals. He currently serves on the board of directors of Photys Therapeutics. Vikas earned an M.B.A. in Health Care Management from the Wharton School of the University of Pennsylvania and a B.A. in Neurobiology from Harvard University.

Jodie Morrison is an accomplished executive and board member with experience from start up through mid-size public biotech and pharmaceutical companies. She currently serves as CEO of Q32 Bio (QTTB), a publicly traded clinical stage biotech company, which she joined from her role as a Venture Partner at the founding investor Atlas Venture. Her prior operating roles include CEO of Cadent Therapeutics (acquired by Novartis in 2021), CEO at Keryx Biopharmaceuticals, Inc. (successful public/public MOE with Akebia Therapeutics), COO at Syntimmune, CEO of eGenesis and CEO of Tokai Pharmaceuticals, Inc. Other prior roles include COO and VP/Head of Clinical and Program Operations at Tokai and various roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc. Ms. Morrison currently serves as a board member at Verve (VERV). She previously held public board roles at Aileron (ALRN), Ribon (private, chairman), Keryx (KERX), prior to CEO role, Akebia (AKBA) and Novus (NVUS). She also serves as a board member at Life Science Cares and on the key advisory board for Harvard Business School’s Blavatnik Fellowship in Life Science Entrepreneurship. Jodie has been awarded the Boston Business Journal’s “Power 50” and “Women to Watch” awards and WEST’s “Making a Difference” award. Ms. Morrison received her business training through the GBEP program at the MIT Sloan School of Management, her clinical research certification from Boston University School of Medicine and her B.A. in neuroscience from Mount Holyoke College.

Dr. Tuyen Ong is currently the Chief Executive Officer at Ring Therapeutics and a CEO-Partner at Flagship Pioneering. Prior to Ring, Dr. Ong was Senior Vice President, Head of the Ophthalmology Franchise at Biogen and was Chief Development Officer at Nightstar Therapeutics until its acquisition by Biogen in 2019. Additionally, while at Nightstar, Dr. Ong was involved with the company’s NASDAQ IPO. Previously, Dr. Ong served as Chief Medical Officer at PTC Therapeutics and was responsible for progressing its pipeline of therapies for rare and genetic diseases. He also held leadership roles at Bausch and Lomb and at Pfizer, with more than 20 years’ experience in clinical and drug development. Dr. Ong was awarded his M.D. from University College London and his M.B.A. from New York University Stern School of Business.